These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22306156)

  • 21. Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum.
    Yu Y; Guo J; Li D; Liu Y; Yu Y; Wang L
    Vaccine; 2018 Aug; 36(32 Pt B):4927-4934. PubMed ID: 30037483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple and rapid method to monitor the disassembly and reassembly of virus-like particles.
    Rajendar B; Sivakumar V; Sriraman R; Raheem M; Lingala R; Matur RV
    Anal Biochem; 2013 Sep; 440(1):15-7. PubMed ID: 23711723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.
    Berg MG; Adams RJ; Gambhira R; Siracusa MC; Scott AL; Roden RB; Ketner G
    Clin Vaccine Immunol; 2014 Sep; 21(9):1224-31. PubMed ID: 24990902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris.
    Bazan SB; de Alencar Muniz Chaves A; Aires KA; Cianciarullo AM; Garcea RL; Ho PL
    Arch Virol; 2009; 154(10):1609-17. PubMed ID: 19756360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assembly of human papillomavirus type-16 virus-like particles: multifactorial study of assembly and competing aggregation.
    Hanslip SJ; Zaccai NR; Middelberg AP; Falconer RJ
    Biotechnol Prog; 2006; 22(2):554-60. PubMed ID: 16599576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
    Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
    Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
    Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
    Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
    Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
    Xu YF; Zhang YQ; Xu XM; Song GX
    Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of HPV16 L1 virus-like particles on the aggregation of non-functionalized gold nanoparticles.
    Palomino-Vizcaino G; Valencia Reséndiz DG; Benítez-Hess ML; Martínez-Acuña N; Tapia-Vieyra JV; Bahena D; Díaz-Sánchez M; García-González OP; Alvarez-Sandoval BA; Alvarez-Salas LM
    Biosens Bioelectron; 2018 Feb; 100():176-183. PubMed ID: 28889068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development a scalable production process for truncated human papillomavirus type-6 L1 protein using WAVE Bioreactor and hollow fiber membrane.
    Sun B; Zhao D; Zhang X; Gu T; Yu X; Sun S; Zhao X; Wei L; Liu D; Yan H; Meng X; Kong W; Xu F; Yang P; Jiang C
    Appl Microbiol Biotechnol; 2016 Feb; 100(3):1231-1240. PubMed ID: 26446387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.
    Módolo DG; Araldi RP; Mazzuchelli-de-Souza J; Pereira A; Pimenta DC; Zanphorlin LM; Beçak W; Menossi M; de Cassia Stocco R; de Carvalho RF
    Vaccine; 2017 Mar; 35(12):1590-1593. PubMed ID: 28222997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.
    Tyler M; Tumban E; Peabody DS; Chackerian B
    Biotechnol Bioeng; 2014 Dec; 111(12):2398-406. PubMed ID: 24917327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disulfide linkage and structure of highly stable yeast-derived virus-like particles of murine polyomavirus.
    Simon C; Klose T; Herbst S; Han BG; Sinz A; Glaeser RM; Stubbs MT; Lilie H
    J Biol Chem; 2014 Apr; 289(15):10411-10418. PubMed ID: 24567335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.
    Cerqueira C; Pang YY; Day PM; Thompson CD; Buck CB; Lowy DR; Schiller JT
    J Virol; 2016 Jan; 90(2):1096-107. PubMed ID: 26559838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform.
    Gallagher JR; Torian U; McCraw DM; Harris AK
    Virology; 2017 Feb; 502():176-187. PubMed ID: 28061386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.